HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.

Gastric cancer is the second leading cause of cancer mortality in the world and its management, especially in advanced stages, has evolved relatively little. In particular, no targeted modality has so far been incorporated to its treatment armamentarium. HER2 overexpression is increasingly recognized as a frequent molecular abnormality, driven as in breast cancer by gene amplification. There is mounting evidence of the role of HER2 overexpression in patients with gastric cancer, and it has been solidly correlated to poor outcomes and a more aggressive disease. Additionally, preclinical data are showing significant antitumor efficacy of anti-HER2 therapies (particularly monoclonal antibodies directed towards the protein) in in vitro and in vivo models of gastric cancer. As a result, several clinical trials are exploring in different settings and with diverse designs the potential of anti-HER2 therapies in gastric cancer patients. This review summarizes the rationale, preclinical evidence, retrospective clinical analyses, and the interim clinical data pertaining HER2 therapies in gastric cancer.

[1]  J. R. Kelley,et al.  Gastric cancer epidemiology and risk factors. , 2003, Journal of clinical epidemiology.

[2]  Y. Hinoda,et al.  Significance of erb B‐2 Gene Product as a Target Molecule for Cancer Therapy , 1994, Scandinavian journal of immunology.

[3]  A. Ochiai,et al.  Expression of HER2 in gastric cancer: Comparison between protein expression and gene amplification using a new commercial kit. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Mori,et al.  Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models , 2007, Cancer Chemotherapy and Pharmacology.

[5]  T. Hirao,et al.  The prognostic significance of amplification and overexpression of c‐met and c‐erb B‐2 in human gastric carcinomas , 1999, Cancer.

[6]  R. Berardi,et al.  Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches. , 2004, Cancer treatment reviews.

[7]  J. Sheu,et al.  Occurrence of microsatellite instability in gastric carcinoma is associated with enhanced expression of erbB-2 oncoprotein. , 1995, Cancer research.

[8]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[9]  J. García-Saenz,et al.  Chemotherapy for gastric cancer. , 2006, World journal of gastroenterology.

[10]  L. Hertle,et al.  Cox-2 and Her2/neu co-expression in invasive bladder cancer. , 2005, International journal of oncology.

[11]  H. P. Wang,et al.  Genetic alterations in gastric cancer: relation to histological subtypes, tumor stage, and Helicobacter pylori infection. , 1997, Gastroenterology.

[12]  H. Hurst,et al.  A novel transcription factor, OB2‐1, is required for overexpression of the proto‐oncogene c‐erbB‐2 in mammary tumour lines. , 1993, The EMBO journal.

[13]  K. Kono,et al.  Status of c‐erbB‐2 in gastric adenocarcinoma: A comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme‐linked immuno‐sorbent assay , 2002, International journal of cancer.

[14]  M. Boiron,et al.  Combination of arabinosyl cytosine, methylglyoxal bis (guanylhydrazone), 6-mercaptopurine and prednisone in the treatment of acute myelocytic leukemia , 1969 .

[15]  H. Hoefler,et al.  The use of molecular biology in diagnosis and prognosis of gastric cancer. , 2000, Surgical oncology.

[16]  A. Jimeno,et al.  Correlation between HER2/neu overexpression/amplification and clinicopathologic parameters in advanced gastric cancer (AGC) patients (pts): A prospective study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Sliwkowski,et al.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). , 1999, Seminars in oncology.

[18]  T. Okuda,et al.  Clinical significance of epidermal growth factor (EGF), EGF receptor, and c‐erbb‐2 in human gastric cancer , 1995, Cancer.

[19]  R. Bast,et al.  Serum levels of HER‐2 neu (C‐erbB‐2) correlate with overexpression of p185neu in human ovarian cancer , 1993, Cancer.

[20]  S. Hirohashi,et al.  Overexpression of c‐erbB‐2 protein in gastric cancer. Its correlation with long‐term survival of patients , 1993 .

[21]  T. Yamane,et al.  Protein Overexpression and Gene Amplification of c-erbB-2 in Pulmonary Carcinomas: A Comparative Immunohistochemical and Fluorescence In Situ Hybridization Study , 2001, Modern Pathology.

[22]  E. Cho,et al.  HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer , 2006, Digestive Diseases and Sciences.

[23]  T. Yamamoto,et al.  The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. , 1986, Science.

[24]  F. Rivera,et al.  Phase II of trastuzumab and cisplatin in patients (pts) with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification , 2007 .

[25]  H. Allgayer,et al.  c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Haerting,et al.  Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  David Cameron,et al.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial , 2007, The Lancet.

[28]  N. Lemoine,et al.  Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. , 1991, British Journal of Cancer.

[29]  J. V. van Sandick,et al.  Prognostic Value of Laurén Classification and c-erbB-2 Oncogene Overexpression in Adenocarcinoma of the Esophagus and Gastroesophageal Junction , 1999, Annals of Surgical Oncology.

[30]  W. Scheithauer,et al.  HER 2/neu protein expression in colorectal cancer , 2006, BMC Cancer.

[31]  S. Kitano,et al.  Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. , 2005, International journal of oncology.

[32]  D. Klimstra,et al.  Analysis of 154 actual five-year survivors of gastric cancer , 2000, Journal of Gastrointestinal Surgery.

[33]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[34]  Heinz Höfler,et al.  Mutations of the human E‐cadherin (CDH1) gene , 1998, Human mutation.

[35]  S. Schnitt.  Breast Cancer in the 21st Century: Neu Opportunities and Neu Challenges , 2001, Modern Pathology.

[36]  H. Sasano,et al.  Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells. , 1993, Human pathology.

[37]  G. Sauter,et al.  Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus , 2007, Modern Pathology.

[38]  T. Kameda,et al.  Expression of ERBB2 in human gastric carcinomas: relationship between p185ERBB2 expression and the gene amplification. , 1990, Cancer research.

[39]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[40]  C. V. D. van de Velde,et al.  Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.

[41]  A. Martín,et al.  Clinical Significance of the Epidermal Growth Factor Receptor and HER2 Receptor in Resectable Gastric Cancer , 2003, Annals of Surgical Oncology.

[42]  J. Isola,et al.  Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  T. Kuroki,et al.  Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. , 1986, Journal of the National Cancer Institute.

[44]  E. Montgomery,et al.  Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. , 2001, Human pathology.

[45]  D. Slamon,et al.  Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. , 1996, Oncogene.

[46]  P. Correa,et al.  Helicobacter pylori and gastric cancer: state of the art. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[47]  A. El‐Naggar,et al.  HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. , 1995, Archives of otolaryngology--head & neck surgery.

[48]  Scott A. Hundahl,et al.  Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. , 2001, The New England journal of medicine.

[49]  F. Roviello,et al.  E-cadherin and hereditary diffuse gastric cancer. , 2007, Surgery.

[50]  Takuma Sasaki,et al.  Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. , 1991, Cancer research.

[51]  S. Cha,et al.  HER-2/neu expression: A major prognostic factor in endometrial cancer , 1992 .

[52]  N. Yamanaka,et al.  Relationship of C‐erbB‐2 protein expression and gene amplification to invasion and metastasis in human gastric cancer , 1993, Cancer.

[53]  L. Tan,et al.  Her-2/neu and breast cancer. , 2001, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[54]  F. Lordick,et al.  3541 POSTER HER2-positive advanced gastric cancer: similar HER2-positivity levels to breast cancer , 2007 .

[55]  Y. Minamisono,et al.  Clinicopathological significance of c‐erbB‐2 protein expression in human gastric carcinoma , 1992, Journal of surgical oncology.

[56]  R. Chaganti,et al.  ERBB2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. , 1994, Cancer research.